Background {#Sec1}
==========

Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant disorders \[[@CR1]\], with an incidence of 1 per 2500 to 3000 individuals, independent of ethnicity and sex \[[@CR2]\]. The most frequent clinical manifestations of NF1 patients include multiple benign neurofibromas, \> 6 alterations of skin pigmentation (café au lait spots), iris (Lisch) nodules, skeletal abnormalities, learning disabilities, cardiovascular disorders and nervous system neoplasms, as well as malignant peripheral nerve sheath tumours \[[@CR3]\]. Furthermore, the occurrence of serious complications increases with age. Therefore, NF1 is a fully penetrant neuro-cutaneous tumour-predisposing disorder with intractable complications.

The most disastrous subtype of NF1 is plexiform neurofibromatosis (PN) \[[@CR4]\]. Approximately 30 to 56% of NF1 patients develop PNs, which may involve the eyelid, orbit and periorbital and facial structures \[[@CR5], [@CR6]\]. Orbital/periorbital PNs (OPPNs) can cause a dramatic change in physical appearance, such as proptosis, ptosis, and facial disfigurement, thus leading to decreased self-esteem, social embarrassment and mood disorders \[[@CR7], [@CR8]\]. In addition, OPPNs can cause various ocular complications, such as optic pathway gliomas, glaucoma, Lisch and choroidal nodules, ultimately resulting in loss of vision, especially during visual maturation \[[@CR6]\] in children.

Neurofibromatosis type 1 is caused by a mutation in the *neurofibromin 1* (*NF1)* tumour-suppressor gene, which comprises 2350 kb and 60 exons on chromosome 17q11 \[[@CR9]\]. The gene product neurofibromin (2818 amino acids) contains a domain with significant homology to Ras GTPase-activating proteins, and it regulates Ras activity \[[@CR10]\]. Therefore, a lack of functional neurofibromin leads to dysregulated Ras signalling and tumourigenesis. PN consists of neoplastic Schwann cells, fibroblasts, perineural cells and mast cells. Neoplastic Schwann cells lack *NF1* gene expression and exhibit elevated levels of activated Ras. In turn, activated Ras initiates a cascade of signalling events, such as activation of Raf and mitogen-activated protein kinase, thus promoting cell proliferation. A previous study revealed numerous *NF1* gene mutations in lung cancer, glioblastoma, melanoma and cutaneous NF1 \[[@CR6], [@CR11], [@CR12]\]; however, to our knowledge, the literature exploring the *NF1* mutations in OPPN patients is rather limited.

Here, we present in detail the clinical characteristics of Chinese patients with OPPN and investigate the *NF1* mutation spectrum.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A retrospective review was performed of consecutive patients diagnosed with OPPNs at Ninth People's Hospital of Shanghai between January 2013 and June 2016. NF1 diagnosis was based on clinical features conforming to at least two of the following National Institutes of Health criteria \[[@CR13]\]: six or more café au lait spots, axillary or inguinal freckling, two or more cutaneous neurofibromatosis, one plexiform NF, characteristic bony defects, optic glioma, two or more iris Lisch nodules, or a first-degree relative with NF1. Moreover, the probands of all families presented with plexiform NF in the orbital or periorbital region. The exclusion criteria were as follows: (1) a follow-up period \< 6 months; and (2) incomplete data collection. We contacted all patients and their relatives who met the inclusion criteria and explained the purpose of the study; the participants were voluntary without any compensation. A total of 36 OPPN patients were included in this study. The OPPNs include 32 hereditary OPPNs (14 families) and 2 sporadic OPPNs. Of the 34 patients from 14 families who met the inclusion criteria, 4 were not reached, and 2 declined to participate for other reasons, such as time or geographic limitations. Of the 28 patients who agreed to return for the follow-up visit, 2 were excluded for incomplete data, leaving a final sample size of 26 patients. All 26 patients had familial OPPN.

Data collection {#Sec4}
---------------

Informed consent was obtained from all patients or their guardians at the follow-up visit. This study adhered to the tenets of the Declaration of Helsinki and was approved by the Shanghai Jiaotong University research ethics committee. The medical records were reviewed. Data collected included patient demographics, clinical characteristics, treatments and final outcomes at follow-up. The demographics consisted of age and sex. The clinical characteristics included the presence of amblyopia, motility disturbances, corneal changes, optic nerve disorders, ptosis, proptosis, canthal abnormalities, cafe au lait spots, facial descent, cheek deformities, bony orbital expansion and soft tissue expansion of eyelids. If the patients' relative had received treatment elsewhere, his/her prior clinical details and pathological sections were retrieved for review. Regarding outcome measures, the duration from the initial diagnosis to the first recurrence was documented.

Mutation identification {#Sec5}
-----------------------

Genomic DNA was isolated from the peripheral blood leukocytes of the participants. We collected genomic DNA samples from at least two affected patients of each family (24 patients in 12 families and 2 unaffected volunteers were chosen as controls). The affected patients shared the same *NF1* mutation site, which was wild-type in the unaffected patients. These mutations were not present in 100 normal subjects or in the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>), predicted to be not tolerated by SIFT (<http://sift.bii.a-star.edu.sg/index.html>) and to be a disease-causing variant by Mutation Taster (<http://www.mutationtaster.org/>). A panel of *NF1* gene exons, splicing sites and promoter regions was designed and sequenced following the instructions of Ion AmpliSeq™ Library Kit 2.0 (Thermo Fisher, USA). A targeted next-generation sequencing (NGS) approach, bioinformatics analyses, and Sanger sequencing were utilized. Library preparation, qualification, and NGS were conducted using the Illumina Hiseq2000 platform (Illumina, Inc., San Diego, CA, USA). Bioinformatics analyses, including read alignments and calculations of coverage and depth, were also carried out according to a previously described protocol \[[@CR14]\]. The following 5 databases were used for annotation of all identified variants, including dbSNP137 (<http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/snp137.txt.gz>.), HapMap Project (<ftp://ftp.ncbi.nlm.nih.gov/hapmap>), 1000 Genomes Project (<ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp>), YH (<http://yh.genomics.org.cn/>), and Exome Variant Server (<http://evs.gs>. washington.edu/EVS/). *NF1* microarray data are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

DNA extraction and sequencing {#Sec6}
-----------------------------

Genomic DNA was extracted from the patients' peripheral blood leukocytes (51,206; QIAGEN, Hilden, Germany). The region of the mutated *NF1* genomic fragments was amplified by polymerase chain reaction (PCR), which was performed with 100 ng genomic DNA, 25 μL 2× GC-rich buffer, 8 μL of a dNTP mixture (2.5 mmol/L), 1 U LA Taq (Takara Biotechnology (Dalian) Co., Ltd), 2 μL (10 μmol/L) of each primer, and ddH~2~O to a final volume of 50 μL. The PCR amplification protocol was as follows: 95 °C for 5 min; 40 cycles at 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s; and a final elongation step at 72 °C for 3 min. The PCR products were then Sanger sequenced to produce a chromatogram. These primers used are listed in Additional file [2](#MOESM2){ref-type="media"}: Table S2.

Statistical analysis {#Sec7}
--------------------

The data were analysed using SAS software (version 9.2, SAS Institute, Inc., Cary, NC). The frequency (percentage) and mean ± standard deviation are reported for categorical and continuous variables, respectively. Means and proportions were compared using Student's t test and the chi-square test (or Fisher's exact test, if appropriate), respectively. All tests were two-sided, and a *p* value \< 0.05 was considered statistically significant. The Kaplan--Meier method was used to assess the cumulative recurrence rate.

Results {#Sec8}
=======

Clinical characteristics of heritable Chinese OPPN patients {#Sec9}
-----------------------------------------------------------

A total of 26 eyes from 26 patients were recruited for this study. Among them, 9 patients (35%) were male and 17 (65%) female. The mean age was 26.9 ± 15.3 years, ranging from 6.0 years to 50.0 years. The mean follow-up period was 35.1 ± 19.6 months. Various clinical characteristics of Chinese patients with OPPN are displayed in Fig. [1](#Fig1){ref-type="fig"}. The most commonly involved area is the upper eyelid (Fig. [2](#Fig2){ref-type="fig"}a). Histologically, the nodules consisted of abundant collagen fibre bundles, nerve sheaths and Schwann cells (Fig. [2](#Fig2){ref-type="fig"}b). Moreover, these OPPN patients often exhibited orbital expansion (Fig. [2](#Fig2){ref-type="fig"}c), facial osteoclasia (Fig. [2](#Fig2){ref-type="fig"}d), intracranial invasion (Fig. [2](#Fig2){ref-type="fig"}e), corneal ulcer and symblepharon (Fig. [2](#Fig2){ref-type="fig"}f). Systematic manifestations, such as café au lait spots (Fig. [2](#Fig2){ref-type="fig"}g) and coexisting extraocular NFs nodules (Fig. 2 h, i), were also found. Fig. 1**a** Genogram of 12 Chinese orbital/periorbital plexiform neurofibromatosis (OPPN) families. The status of affected (black symbol) represents OPPN disease. **b** Various clinical appearances of Chinese OPPN patients Fig. 2Clinical manifestations of orbital/periorbital plexiform neurofibromatosis (OPPN) patients. **a** OPPN located in the upper eyelid. Left: Computed tomography (CT) of infiltrative OPPN. Right upper: Magnetic resonance imaging (MRI) of infiltrative OPPN. The arrow indicates the orbital infiltration of OPPN and displacement of the orbital contents. Right below: General view of a dissected OPPN. **b** Pathological feature of OPPN: abundant collagen fibres and nerve sheaths. Scale bar: 40 μm. **c** CT images of OPPN resulting in orbital bone destruction. The arrow indicates the area of orbital osteoclasia. **d** CT images of facial infiltration of OPPN. The arrow indicates the infiltrated area of OPPN. **e** CT images of intracranial infiltration of OPPN. The arrow indicates the intracranial infiltration. **f** Upper: corneal ulceration. Below: Surgery-induced symblepharon. **g** Café au lait spots. **h** Coexisting extraocular OPPN. **i** X-ray images showing an enormous mass in the right chest of OPPN patients

Demographic and clinical characteristics were compared between the patients and their previous generation, and the results are summarized in Table [1](#Tab1){ref-type="table"}. Most patients exhibited OPPN in the same laterality as their parents and/or grandparents. Of note, significantly earlier onset (*p* = 0.001) and more severe symptoms were observed in successive generations. Additionally, compared to their ancestors, a larger proportion of patients displayed amblyopia (*p* = 0.034), motility disorders (*p* = 0.009) and bony orbital expansion (*p* = 0.019). However, no statistical significance was found regarding the following: sex; the presence of ptosis; proptosis; cafe au lait spots; facial descent; cheek deformities; soft tissue expansion of the eyelids or corneal or optic nerve; or canthal abnormalities. Among the 12 patients who underwent reconstruction surgery at our hospital, 10 (83.3%) experienced recurrence. Based on Kaplan-Meier survival estimates, the 1-year recurrence rate was 83.3%, and the median duration to the initial recurrence was 7.0 months (95% confidence interval: 5.30--8.70 months). Table 1Comparisons of demographic and clinical characteristics between the patients and affected members of the previous generationTotal (*n* = 26)Patient (*n* = 12)Parents and/or grandparents (*n* = 14)*p*Sex0.127 Male9(35%)6(50%)3(21%) Female17(65%)6(50%)11(79%)Age of onset16.0 ± 10.19.5 ± 4.521.6 ± 10.40.001\*Amblyopia0.034\* Present16(62%)10(83%)6(43%) Absent10(38%)2(17%)8(57%)Motility disorders0.009\* Present17(65%)11(92%)6(43%) Absent9(35%)1(8%)8(57%)Corneal abnormalities0.490 Present5(19%)3(25%)2(14%) Absent21(81%)9(75%)12(86%)Optic nerve abnormalities0.449 Present3(12%)2(17%)1(7%) Absent23(88%)10(83%)13(83%)Ptosis0.345 Present25(96%)12(100%)13(93%) Absent1(4%)0(0%)1(7%)Proptosis0.127 Present9(35%)6(50%)3(21%) Absent17(65%)6(50%)11(79%)Canthal abnormalities0.356 Present22(85%)11(92%)11(79%) Absent4(15%)1(8%)3(21%)Café au lait spots1.000 Present26(100%)12(100%)14(100%) Absent0(0%)0(0%)0(0%)Facial descent0.126 Present11(44%)7(58%)4(29%) Absent15(56%)5(42%)10(71%)Cheek deformities0.126 Present11(44%)7(58%)4(28%) Absent15(56%)5(42%)10(72%)Bony orbital expansion0.019\* Present9(35%)7(58%)2(14%) Absent17(65%)5(42%)12(86%)Soft tissue expansion of eyelids0.173 Present25(96%)12(100%)12(86%) Absent1(4%)0(0%)2(14%)\*Statistically significant

Novel *NF1* mutations in Chinese OPPN families {#Sec10}
----------------------------------------------

Mutation analysis revealed a wide spectrum of *NF1* mutations in this cohort (Table [2](#Tab2){ref-type="table"}), with fourteen different mutations identified. Eleven (91.7%) OPPN families presented *NF1* mutations, and 6 identified mutations were novel. Nine (64.3%) of the fourteen identified mutations were distributed in exons, three (21.4%) in splicing sites and one (7%) in an intron. Among exon mutations, three (33.3%) nonsense mutations causing premature termination of neurofibromin were detected; three frameshift mutations and three missense mutations were also discovered. These mutations were evenly distributed from exon 12 to intron 49 of the gene. Additionally, no common mutations were detected across the families, suggesting the absence of mutational hot spots. The regions of *NF1* genomic DNA mutation sited were amplified by PCR (Fig. [3](#Fig3){ref-type="fig"}a), and a Sanger chromatogram confirmed novel mutations (Fig. [3](#Fig3){ref-type="fig"}b). Table 2Mutation spectrum of *neurofibromin 1* in Chinese orbital-periorbital neurofibromatosis patientsFamily numberNF1 mutationRegionMutation typeMutation siteProteinNovel/ previously described1YesExon 49Frameshift deletionNM_000267: exon49: c.7385_7394del: p.P2462fs,NM_001042492: exon50: c.7448_7457del: p.P2483fsP2462fspreviously described2YesSplicing/NM_001042492: exon51: c.7458-1G \> C,NM_000267: exon50: c.7395-1G \> C/Novel3YesExon 17MissenseSNVNM_000267: exon17:c.C1919T: p.T640I, NM_001042492: exon17:c.C1919T: p.T640Ip.T640INovelExon 18Stop gainNM_000267: exon18:c.C2041T: p.R681X, NM_001042492: exon18:c.C2041T: p. R681Xp.R681Xpreviously described4YesExon 20Frameshift deletionNM_000267: exon20: c.2385delA: p.P795fs, NM_001042492: exon20: c.2385delA:p.P795fsp.P795fsNovel5YesExon 16Frameshift deletionNM_000267: exon16: c.1754_1757del: p.L585 fs, NM_001042492: exon16: c.1754_1757del:p.L585 fsp.L585 fsNovelExon 17MissenseSNVNM_000267: exon17: c. A1933G: p.M645 V, NM_001042492: exon17:c. A1933G:p.M645 Vp.M645 Vpreviously described6YesSplicing/NM_001042492: exon36: c.4725-1G \> A,NM_000267: exon35: c.4662-1G \> A/previously described7YesExon 21MissenseSNVNM_000267: exon21: c. A2683G: p.M895 V, NM_001042492:exon21:c.A2683G: p.M895 Vp.M895 Vpreviously describedSplicing/NM_001042492: exon16: c.1845 + 1G \> A,NM_000267: exon16: c.1845 + 1G \> A/previously described8No/////9YesExon 12Stop gainNM_000267: exon34:c.C4537T: p.R1513X, NM_001042492: exon35:c.C4600T: p.R1534Xp.R440Xpreviously described10YesIntron/NF1:Ch17: 29665038: T \> A/Novel11YesSplicing/NM_001042492: exon48: c.7063-2A \> G,NM_000267: exon47: c.7000-2A \> G/Novel12YesExon 34Stop gainNM_000267: exon34:c.C4537T: p.R1513X, NM_001042492: exon35:c.C4600T: p.R1534Xp.R1513Xpreviously described Fig. 3PCR gel images and Sanger chromatogram indicating novel *NF1* mutations. **a** PCR gel images of each mutated *NF1* genomic fragment. **b** Sanger chromatogram of each novel *NF1* mutation

Discussion {#Sec11}
==========

OPPN is a severe form of NF with a short, non-progressive period \[[@CR6]\]. This study constitutes the largest cohort of heritable OPPNs. The successive generation presented earlier onset and exhibited more severe ocular signs, including amblyopia, motility disorders and bony orbital expansion, when compared with their parents or grandparents. In general, earlier onset can result from an increased awareness of the disease in a family. Each Chinese family with OPPN in our study shared one common *NF1* mutation; however, the underlying reason for the aggravated symptoms in the successive generation remains unclear. Notably, no common mutations were detected across the OPPN families, indicating that there were no mutational hot spots. Additionally, no obvious genotype-phenotype correlation was observed in the OPPN patients.

To date, more than 2000 different *NF1* mutations have been identified in Human Gene Mutation Database \[[@CR15]\]. The *NF1* gene has one of the highest mutation rates, and different populations have different sets of recurrent exonic mutations \[[@CR6], [@CR16], [@CR17]\]. Our study detected 6 novel mutations in 26 OPPN patients among 12 families. Of note, an intron mutation (NF1:Ch17: 29665038: T \> A) was identified in the patients of the 10th family. Although two patients shared this mutation and this mutation was not present in unaffected individuals, we cannot confirm whether this intronic mutation is related to the pathogenesis of OPPN. We performed a literature review as well as a comparison of *NF1* mutations in Chinese and patients from other parts of the world \[[@CR16], [@CR17]\]. The results indicated that the missense mutation rate in Italian patients (58.9%) was significantly higher (all *p* = 0.01) than in Korean (38.5%) and Chinese (21.4%) patients (Table [3](#Tab3){ref-type="table"}). To date, there has been little evidence with regard to the genotype-phenotype correlation in *NF1*. Although OPPN patients in one family share a common *NF1* mutation, symptoms can vary greatly. This might be due to differences in age, sex and other epigenetic factors \[[@CR18]\]. For example, a family-based association study revealed a strong association between the lncRNA *ANRIL* and the number of plexiform neurofibromas \[[@CR19]\]. Table 3Comparisons of *NF1* mutation spectra between Chinese and patients from other parts of the worldChinese patients (*n* = 14)Korean patients (*n* = 52)Italian patients (*n* = 73)p1p2Novelty0.3950.591Reported8(57.1)36(69.2)36(49.3)Novel6(42.8)16(30.8)37(50.7)Single-base mutation6(42.9)30(57.7)49(67.1)0.3220.085Nonsense3(21.4)10(19.2)6(8.2)0.8540.137Missense3(21.4)20(38.5)43(58.9)0.2350.010\*Splicing mutation4(28.6)8(15.4)18(24.7)0.2560.758Intron1(7.14)//NANAFrameshift deletion3(21.4)8(15.4)18(24.7)0.5900.796Insertion0(0)3(5.8)1(1.4)0.3580.660Data are presented as n(%)\*Statistically significant; p1: Chinese versus Korean patients \[[@CR17]\]; p2: Chinese versus Italian patients \[[@CR16]\]

Among NF1 patients, 35--60% of cases are familial and others sporadic \[[@CR16], [@CR17]\]. We initially enrolled 34 patients, including 32 (94.12%) familial and 2 (5.89%) sporadic cases. However, two sporadic cases were excluded due to loss of contact; thus, all of the OPPN cases were hereditary. The percentage of familial NF in out study was much higher than that previously reported, which could be partially explained by the following reasons: 1) increased awareness of this disease for hereditary cases, 2) selection bias with a sample size of 26 OPPNs and 3) OPPNs presented with higher genetic predisposition than did other types of NFs.

This study should be regarded as an initial exploration of the clinical characteristics and genetic patterns of Chinese patients with OPPN. Caution should be taken when interpreting the findings due to the following limitations. The sample size was small, though the low incidence of this disease makes it difficult to recruit a larger cohort of patients. In addition, this study was conducted in a single tertiary institution, and all participants were of Chinese Han ethnicity. All these factors may cause selection bias, and our findings may not be generalizable to all Chinese OPPN patients. Thus, we will continue to seek data sets from other medical centres for future validation studies. Nevertheless, we attempted to circumvent these limitations as follows: our study is the largest cohort of Chinese patients with familial OPPN to date, and this study involved a single surgeon and used objective statistical methods, which help to minimize selection and confounding biases.

Conclusion {#Sec12}
==========

Earlier onset and more severe symptoms were displayed in successive generations of patients with heritable OPPN. Special attention should be paid to the successive generations of OPPN patients. Considering that some of the detected mutations were novel, comprehensive *NF1* mutation analysis is valuable for genetic counselling. To our knowledge, this is the first study to provide detailed clinical characteristics and the *NF1* mutation spectrum for Chinese patients with heritable OPPN. Therefore, a larger cohort from multiple clinical centres is required to fully validate our findings.

Additional files
================

 {#Sec13}

Additional file 1:Raw NF1 microarray sequencing data of OPPNs. (XLS 139 kb) Additional file 2:Primers used in the study. (DOCX 12 kb)
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